Equities analysts expect Theravance Biopharma Inc (NASDAQ:TBPH) to post sales of $13.92 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Theravance Biopharma’s earnings. The highest sales estimate is $16.00 million and the lowest is $12.45 million. Theravance Biopharma reported sales of $23.48 million during the same quarter last year, which indicates a negative year-over-year growth rate of 40.7%. The company is expected to announce its next quarterly earnings results on Wednesday, August 7th.

On average, analysts expect that Theravance Biopharma will report full-year sales of $56.16 million for the current financial year, with estimates ranging from $45.78 million to $65.00 million. For the next financial year, analysts anticipate that the firm will report sales of $102.99 million, with estimates ranging from $74.18 million to $129.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that follow Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.14). The company had revenue of $5.34 million during the quarter, compared to the consensus estimate of $16.45 million. Theravance Biopharma had a negative return on equity of 2,631.71% and a negative net margin of 388.61%.

A number of research analysts have recently commented on TBPH shares. Piper Jaffray Companies cut shares of Hershey from a “neutral” rating to an “underweight” rating and upped their price target for the stock from $122.00 to $125.00 in a report on Wednesday, June 19th. BidaskClub upgraded shares of Zillow Group from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 2nd. Finally, Cantor Fitzgerald set a $9.00 price target on shares of Evofem Biosciences and gave the stock a “buy” rating in a report on Friday, April 12th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $43.40.

Shares of NASDAQ TBPH traded up $0.32 during mid-day trading on Friday, reaching $17.34. The company had a trading volume of 192,336 shares, compared to its average volume of 260,218. The stock’s 50-day moving average price is $16.66. The firm has a market cap of $973.47 million, a PE ratio of -4.35 and a beta of 1.76. Theravance Biopharma has a 52 week low of $15.18 and a 52 week high of $35.48.

In other Theravance Biopharma news, Director Donal O’connor sold 4,000 shares of the stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $20.46, for a total transaction of $81,840.00. Following the transaction, the director now directly owns 30,244 shares in the company, valued at approximately $618,792.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.60% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the business. DekaBank Deutsche Girozentrale boosted its holdings in Theravance Biopharma by 21.9% in the first quarter. DekaBank Deutsche Girozentrale now owns 11,700 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 2,100 shares in the last quarter. Fosun International Ltd acquired a new position in Theravance Biopharma in the first quarter valued at approximately $2,386,000. NJ State Employees Deferred Compensation Plan boosted its holdings in Theravance Biopharma by 6.9% in the first quarter. NJ State Employees Deferred Compensation Plan now owns 31,142 shares of the biopharmaceutical company’s stock valued at $706,000 after purchasing an additional 2,000 shares in the last quarter. SG Americas Securities LLC acquired a new position in Theravance Biopharma in the first quarter valued at approximately $156,000. Finally, BNP Paribas Arbitrage SA boosted its holdings in Theravance Biopharma by 882.7% in the first quarter. BNP Paribas Arbitrage SA now owns 9,965 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 8,951 shares in the last quarter. Institutional investors own 84.75% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Read More: What is Net Asset Value (NAV)?

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.